Related Experiment Video
Updated: Sep 23, 2026

Ultrasonographic Evaluation of Salivary Glands for Sjogren's Syndrome: Diagnostic and Monitoring Insights
Published on: October 13, 2023
Managing Sjögren's Disease in Pediatric Patients
Sara M Stern1, Ludovic Trinquart2,3, Hermine I Brunner4
1Division of Rheumatology, Department of Pediatrics, University of Utah, 81 N. Mario Capecchi Dr, Salt Lake City, UT, 84113, USA. sara.stern@hsc.utah.edu.
Abstract:
Over the past decade, therapeutic development in adult Sjögren's disease (SjD) has accelerated substantially. Multiple targeted agents directed at B-cell survival, co-stimulation, autoantibody recycling, and immune regulation are advancing through late-phase clinical development. As of August 2026, there are no US Food and Drug Administration-approved disease-modifying or immunomodulatory therapies specifically indicated to treat the underlying autoimmunity of SjD. US Food and Drug Administration approvals in adults are limited to symptomatic treatment of sicca (dryness) symptoms, particularly xerostomia (dry mouth). Treatment of childhood SjD remains off-label and is supported by a limited evidence base consisting largely of case reports, case series, registry abstracts, and clinician survey data. B-cell-targeted medicines and conventional disease-modifying anti-rheumatic drugs have been used off-label in SjD, including childhood SjD. In this review, we compare the clinical phenotype of childhood SjD with adult SjD, summarize the therapies currently used in children and the evidence supporting them, and propose a framework for prioritizing adult SjD therapeutics for pediatric development. The inflammatory phenotype of childhood SjD provides a strong biologic rationale for the study of selected targeted therapies, while underscoring the need for staged pediatric development, phenotype-enriched trials, and outcome measures suited to glandular and systemic disease in children. The highest-priority candidates for pediatric study are discussed based on available adult data and current approval in children for other pediatric diseases.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Tonsillitis II: Management
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Pharmacokinetics in Pediatric Patients: Drug Excretion
